Panoply of immunotherapies for malignant and nonmalignant hematological diseases. Passive immunotherapies consist of molecules from ex vivo activated cells that, following infusion or adoptive transfer, compensate for deficient immune functions. Active immunotherapies stimulate the patient’s immune system via a vaccine or inhibit an important checkpoint of T-cell activation. Antiviral CTLs, EBV (Epstein-Barr virus), CMV (cytomegalovirus), adenovirus, HHV6 (human herpesvirus 6), cytotoxic T cells; BiTEs and TriKEs, bi- and tri-specific T-cell engagers; DC, dendritic cells; DLI, donor lymphocyte injection following allogeneic hematopoietic cell transplantation; EBV CTL, nonengineered Epstein-Barr virus–specific cytotoxic T lymphocyte used to treat EBV⁺ lymphomas; ILC2, innate lymphocyte 2; mAbs, monoclonal antibodies; MDSCs, myeloid-derived suppressive cells; MSCs, mesenchymal stem cells; NKT, natural killer T cells; TIL, tumor-infiltrating T cells that have been extracted from the autologous tumor and expanded in IL-2; Treg, regulatory T cell.